How should sequences with defined regions separated by undisclosed gaps be represented in a Sequence Listing XML?
The MPEP 2412.05(e) provides specific guidance on how to represent sequences with defined regions separated by undisclosed gaps in a Sequence Listing XML: “A nucleotide and/or amino acid sequence that contains regions of specifically defined residues separated by one or more gaps of an unknown or undisclosed number of residues must be listed in the…
Read MoreHow are sequences with known numbers of ‘n’ or ‘X’ residues between defined regions represented in a Sequence Listing XML?
According to MPEP 2412.05(e), sequences with known numbers of ‘n’ or ‘X’ residues between defined regions are represented as a single sequence in the Sequence Listing XML. The MPEP states: “A nucleotide and/or amino acid sequence that contains regions of specifically defined residues separated by one or more regions of contiguous ‘n’ or ‘X’ residues,…
Read MoreHow should a sequence constructed from non-contiguous segments be represented in a Sequence Listing XML?
According to MPEP 2412.05(e), a sequence constructed as a single continuous sequence from non-contiguous segments must be listed in the Sequence Listing XML as a single sequence with its own identifier. Specifically, the MPEP states: “A nucleotide and/or amino acid sequence that is constructed as a single continuous sequence derived from one or more non-contiguous…
Read MoreWhat is the significance of WIPO Standard ST.26 in representing sequences in patent applications?
WIPO Standard ST.26 plays a crucial role in guiding the representation of nucleotide and amino acid sequences in patent applications. The MPEP 2412.05(e) frequently references this standard when describing how to handle various sequence scenarios in the Sequence Listing XML. For example: Paragraph 35 of ST.26 is cited for handling sequences constructed from non-contiguous segments.…
Read More